2023-11-11T11:06:22-06:00 2022-12-31 861065772 DELOITTE TAX LLP 50 SOUTH SIXTH STREET MINNEAPOLIS MN 55402 990 2022-01-01 821808476 BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE BILL 8577022108 ONE KENDALL SQ BLDG 600 6-301 CAMBRIDGE MA 02139 MAHENDRA PATTNI TREASURER 8577022108 2023-11-03 1 MAHENDRA PATTNI 999009999 0 ANNE FULTON P00941863 6123974000 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z MAHENDRA PATTNI ONE KENDALL SQ BLDG 600 6-301 CAMBRIDGE MA 02139 12321803 0 X WWW.GATESMRI.ORG X 2017 WA THE GATES MRI ENGAGES DIRECTLY IN THE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH ONE OR MORE HOSPITALS FOR THE PURPOSE OF ADDRESSING MAJOR CAUSES OF ILLNESS AND DEATH IN LOW-AND LOWER-MIDDLE-INCOME COUNTRIES. 5 1 138 0 0 0 216721752 12245754 0 0 16207 58534 10573 17515 216748532 12321803 0 0 0 0 34945176 43773018 0 0 0 70180846 93444166 105126022 137217184 111622510 -124895381 277647725 186459426 17580390 51302471 260067335 135156955 X THE GATES MRI ENGAGES DIRECTLY IN THE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH ONE OR MORE HOSPITALS FOR THE PURPOSE OF ADDRESSING MAJOR CAUSES OF ILLNESS AND DEATH IN LOW-AND LOWER-MIDDLE-INCOME COUNTRIES. 0 0 68753923 BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE ("GATES MRI") IS ALIGNED WITH THE PURPOSE OF THE BILL & MELINDA GATES FOUNDATION AND GUIDED BY THE VISION THAT EVERY PERSON DESERVES THE OPPORTUNITY TO LEAD A HEALTHY AND PRODUCTIVE LIFE. THE GATES MRI IS DEDICATED TO THE RESEARCH, DEVELOPMENT, AND EFFECTIVE USE OF NOVEL BIOMEDICAL INTERVENTIONS ADDRESSING SUBSTANTIAL GLOBAL HEALTH CONCERNS FOR WHICH THE REQUIRED DEVELOPMENT INVESTMENT BY TRADITIONAL BIOPHARMACEUTICAL ORGANIZATIONS IS LACKING. THE GATES MRI WORKS WITH COLLABORATING PARTNERS AND ORGANIZATIONS, COORDINATING AND DRIVING BIOPHARMACEUTICAL RESEARCH AND DEVELOPMENT ACTIVITIES, INCLUDING PRE-CLINICAL DEVELOPMENT AND CLINICAL DEVELOPMENT. IN ADDITION TO THE TUBERCULOSIS WORK NOTED IN 4(B) THE MRI FOCUSES ON PROGRAMS AIMED AT REDUCING THE BURDEN OF MALARIA, DIARRHEAL DISEASES, AND MATERNAL, NEWBORN, AND CHILD ILLNESSES WORLDWIDE. 52391548 THE GATES MRI'S LARGEST PROGRAM AREA FOCUSES ON REDUCING THE BURDEN OF TUBERCULOSIS THROUGH THE RESEARCH AND DEVELOPMENT OF NOVEL THERAPEUTICS AND VACCINE CANDIDATES, INCLUDING THROUGH THE CONDUCT OF CLINICAL TRIALS. 121145471 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 34 0 1 138 1 0 0 0 0 0 0 0 0 0 0 0 0 X 5 1 1 0 1 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 MA WA CA X X JENNIFER DEGER 2067093100 500 FIFTH AVENUE N SEATTLE WA 98109 TREVOR MUNDEL DIRECTOR, BOARD CHAIR 3.00 40.00 X 0 1249224 72659 CAROLYN AINSLIE DIRECTOR 2.00 40.00 X 0 879108 74725 TONI HOOVER DIRECTOR 2.00 40.00 X 0 572338 73105 HELENE MADONICK DIRECTOR 2.00 0.00 X 0 32038 0 SUSAN DESMOND-HELLMANN DIRECTOR (END 12/31/22) 2.00 0.00 X 0 0 0 EMILIO EMINI CHIEF EXECUTIVE OFFICER 40.00 0.00 X 778982 0 70056 MAHENDRA PATTNI TREASURER 40.00 0.00 X 448355 0 83975 SALLY JENNINGS SECRETARY 40.00 0.00 X 416831 0 83783 MICHAEL DUNNE CHIEF MEDICAL OFFICER, HEAD OF DEV. 40.00 0.00 X 725742 0 87774 DEBRA WEISS CHIEF OPERATING OFFICER 40.00 0.00 X 585274 0 71664 PIPER TRELSTADSTART 1322 HEAD OF CHEM, MFG, CONTROL 40.00 0.00 X 565246 0 84218 LEE BANSIL HEAD OF GLOBAL STRATEGIC COMMUNICATIONS 40.00 0.00 X 538738 0 83665 CHARLES WELLS HEAD OF THERAPEUTICS DEVELOPMENT 40.00 0.00 X 485103 0 71888 ALEXANDER SCHMIDT HEAD OF VACCINE DEVELOPMENT 40.00 0.00 X 471658 0 84570 ANTONIO GONZALEZ LOPEZ CLINICAL DEVELOPMENT LEADER 40.00 0.00 X 477427 0 71992 JANIE PARRINO CLINICAL DEVELOPMENT LEADER 40.00 0.00 X 461406 0 58970 MARY THISTLE END 42922 FORMER TREASURER, CHIEF OF STAFF 40.00 0.00 X 78357 0 18749 JARED SILVERMANEND 123121 HEAD OF TRANSLATIONAL DISCOVERY 40.00 0.00 X 487966 0 86684 TARYN ROGALSKI-SALTER HEAD OF GLOBAL REG STRAT(END 1/3/22) 40.00 0.00 X 465694 0 74632 6986779 2732708 1253109 117 1 1 0 PPD DEVELOPMENT LP 929 NORTH FRONT STREET WILMINGTON NC 28401 CLINICAL RESEARCH ORGANIZATION 10556478 IQVIA RDS INC 4820 EMPEROR BLVD DURHAM NC 27703 CLINICAL RESEARCH ORGANIZATION 9185225 LOGIX INC 1601 TRAPELO ROAD SUITE 230 WALTHAM MA 02451 SUPPLEMENTAL STAFFING & PLACEMENT SVCS. 7234236 MMS HOLDINGS INC 6880 COMMERCE BLVD CANTON MI 48187 CLINICAL DATA MANAGEMENT SERVICES 3068418 BARC SA 11 NAPIER ROAD JOHANNESBURG SF 2092 CLINICAL LAB SERVICES 2911719 78 11408165 837589 12245754 58534 58534 CURRENCY CONVERSION 900099 17515 17515 17515 12321803 0 0 76049 X 4001901 1963594 2038307 97106 97106 28758306 24891234 3867072 3901472 3389396 512076 5223006 4035348 1187658 1791227 1527799 263428 779842 649731 130111 200750 200750 74947617 70986924 3960693 652655 515727 136928 3111989 2362810 749179 3500000 3500000 5508062 4747217 760845 1259601 1125827 133774 66654 64653 2001 1814132 1814132 192562 181554 11008 RECRUITING 777500 666250 111250 FURNITURE AND EQUIPMENT 333275 269830 63445 DUES AND SUBSCRIPTION 197496 166098 31398 OTHER TAXES AND FEES 102031 101479 552 137217184 121145471 16071713 0 0 35259489 50468880 222963535 94008356 46821 15753 4820096 4484872 44354196 7566160 13832666 36788036 725118 693529 277647725 186459426 17580390 51302471 17580390 51302471 X 260067335 135156955 0 0 260067335 135156955 277647725 186459426 X -124895381 -15000 X 0 1 X 1 0 X UNIVERSITY OF WASHINGTON SEATTLE WA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 15438320 3870759 11567561 904404 356386 548018 28011472 3339015 24672457 36788036 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 8055590 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 4131809 SOUTH ASIA 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 872424 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 255361 NORTH AMERICA 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 116908 SOUTH AMERICA 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 37469 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 1140 0 0 0 0 0 0 13470701 0 13470701 1 0 0 0 0 0 PART III ACCOUNTING METHOD: SCHEDULE F, PART VI, LINE 1: THERE WERE TRANSFERS OF CASH TO FOREIGN CORPORATIONS BUT THEY WERE NOT OF THE TYPE DESCRIBED IN SECTION 6038B(A)(1)(A), 367(D), OR 367(E) SO NO FORM 926 WAS REQUIRED TO BE FILED. X X 1 1 X X X 0 0 0 0 0 0 0 1 0 TREVOR MUNDEL DIRECTOR, BOARD CHAIR 0 1188822 0 0 0 60402 0 45750 0 26909 0 1321883 0 0 CAROLYN AINSLIE DIRECTOR 0 825032 0 132 0 53944 0 45750 0 28975 0 953833 0 0 EMILIO EMINI CHIEF EXECUTIVE OFFICER 746668 0 0 0 32314 0 45750 0 24306 0 849038 0 0 0 MICHAEL DUNNE CHIEF MEDICAL OFFICER, HEAD OF DEV. 686139 0 10000 0 29603 0 45750 0 42024 0 813516 0 0 0 DEBRA WEISS CHIEF OPERATING OFFICER 546527 0 10000 0 28747 0 45750 0 25914 0 656938 0 0 0 PIPER TRELSTADSTART 1322 HEAD OF CHEM, MFG, CONTROL 461376 0 71500 0 32370 0 45750 0 38468 0 649464 0 0 0 TONI HOOVER DIRECTOR 0 542925 0 0 0 29413 0 45750 0 27355 0 645443 0 0 LEE BANSIL HEAD OF GLOBAL STRATEGIC COMMUNICATI 384292 0 37680 0 116766 0 45750 0 37915 0 622403 0 0 0 JARED SILVERMANEND 123121 HEAD OF TRANSLATIONAL DISCOVERY 474631 0 0 0 13335 0 45750 0 40934 0 574650 0 0 0 CHARLES WELLS HEAD OF THERAPEUTICS DEVELOPMENT 444719 0 10173 0 30211 0 45750 0 26138 0 556991 0 0 0 ALEXANDER SCHMIDT HEAD OF VACCINE DEVELOPMENT 425572 0 10346 0 35740 0 45750 0 38820 0 556228 0 0 0 ANTONIO GONZALEZ LOPEZ CLINICAL DEVELOPMENT LEADER 399519 0 0 0 77908 0 45750 0 26242 0 549419 0 0 0 TARYN ROGALSKI-SALTER HEAD OF GLOBAL REG STRAT(END 1/3/22) 427222 0 0 0 38472 0 45750 0 28882 0 540326 0 0 0 MAHENDRA PATTNI TREASURER 422292 0 0 0 26063 0 45750 0 38225 0 532330 0 0 0 JANIE PARRINO CLINICAL DEVELOPMENT LEADER 370974 0 81500 0 8932 0 45750 0 13220 0 520376 0 0 0 SALLY JENNINGS SECRETARY 403056 0 0 0 13775 0 45750 0 38033 0 500614 0 0 0 MARY THISTLE END 42922 FORMER TREASURER, CHIEF OF STAFF 73564 0 0 0 4793 0 11035 0 7714 0 97106 0 0 0 PART I, LINE 1A THE TRAVEL POLICY, APPLICABLE TO ALL EMPLOYEES, ALLOWS FOR FIRST-CLASS AIR TRAVEL ON DOMESTIC RED-EYE FLIGHTS DEPARTING AFTER 9:00 PM THAT EXCEED FIVE HOURS IN DURATION. RELOCATION PACKAGES ARE GENERALLY PROVIDED TO NEW EMPLOYEES WHO RESIDE MORE THAN 50 MILES OUTSIDE OF CAMBRIDGE, MASSACHUSSETTS. THE ORGANIZATION GROSSES UP TAXABLE RELOCATION BENEFITS AND NOMINAL SPOT AWARDS FOR EXEMPLARY PERFORMANCE. PART I, LINE 7 ALL EMPLOYEES ARE ELIGIBLE TO RECEIVE HIGH IMPACT BONUSES, ANNUALLY. THESE BONUSES ARE DISCRETIONARY TO BE PAID BASED ON PREDETERMINED FIXED AMOUNTS (BETWEEN $2,500 AND $10,000) AND THE TOTAL AMOUNT PAID IS DETERMINED BASED ON PERFORMANCE AND THE IMPACT ON THE ORGANIZATION. DURING 2022, GATES MEDICAL RESEARCH INSTITUTE PAID OUT HIGH IMPACT BONUSES, INCLUDING TO INDIVIDUALS LISTED ON PART VII, SECTION A. PART VII, SECTION A, LINE 1: TOTAL ANNUAL COMPENSATION IS REPORTED FOR ALL DIRECTORS, OFFICERS AND KEY EMPLOYEES REGARDLESS OF THE LENGTH OF TIME ACTIVELY SERVING AS A DIRECTOR, OFFICER, OR KEY EMPLOYEE OF GATES MEDICAL RESEARCH INSTITUTE DURING 2022. FORM 990, PART VI, SECTION A, LINE 2 CAROLYN AINSLIE, TREVOR MUNDEL, TONI HOOVER, AND HELENE MADONICK HAVE A BUSINESS RELATIONSHIP AS CURRENT OR FORMER EMPLOYEES OF THE BILL & MELINDA GATES FOUNDATION WHO RECEIVED COMPENSATION DURING THE YEAR. FORM 990, PART VI, SECTION A, LINE 4 GATES MEDICAL RESEARCH INSTITUTE ADOPTED AMENDED AND RESTATED BYLAWS IN 2022. SIGNIFICANT CHANGES INCLUDE THE FOLLOWING: - CONFORM WITH THE NEW WASHINGTON STATE NONPROFIT CORPORATION ACT, - AMEND THE TERMS OF ARTICLE 7 REGARDING INDEMNIFICATION OF DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS, AND - ADD ARTICLE 8 REGARDING BOARD ACTION IN AN EMERGENCY. FORM 990, PART VI, SECTION A, LINE 6 THE SOLE MEMBER OF BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE IS BILL & MELINDA GATES FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A BILL & MELINDA GATES FOUNDATION, THE SOLE MEMBER OF BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE, HAS THE AUTHORITY TO APPOINT AND REMOVE DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7B BILL & MELINDA GATES FOUNDATION, THE SOLE MEMBER OF BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE, HAS THE AUTHORITY TO AMEND THE ARTICLES OF INCORPORATION, ADOPT A PLAN OF MERGER OR CONSOLIDATION, AUTHORIZE THE SALE, LEASE, OR EXCHANGE OF ALL OR SUBSTANTIALLY ALL OF THE ASSETS OF THE ORGANIZATION, AUTHORIZE THE VOLUNTARY DISSOLUTION OF THE ORGANIZATION AND ADOPTION OF A PLAN FOR THE DISTRIBUTION OF THE ASSETS OF THE ORGANIZATION, IN ACCORDANCE WITH THE ORGANIZATION'S ORGANIZATIONAL DOCUMENTS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY A THIRD-PARTY ACCOUNTANT. AFTER PREPARATION, IT IS REVIEWED IN DETAIL BY THE TREASURER OF THE INSTITUTE, AND THE TAX TEAM AND CONTROLLER OF BILL & MELINDA GATES FOUNDATION, THE SOLE MEMBER OF BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE. A COPY OF THE FORM 990 IS PROVIDED TO THE ENTIRE BOARD PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE CONSIDERED "COVERED PERSONS" FOR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY, AND AS SUCH, ARE REQUIRED TO DISCLOSE ANY RELATIONSHIPS THAT COULD GIVE RISE TO CONFLICTS OF INTEREST INVOLVING THE ORGANIZATION. IN ADDITION, ANY TRANSACTIONS BETWEEN THE ORGANIZATION AND ANY OF THESE INDIVIDUALS (OR THEIR FAMILY MEMBERS OR AN AFFILIATED ENTITY) MUST BE DISCLOSED TO THE SECRETARY. IF THE SECRETARY HAS A POTENTIAL CONFLICT OF INTEREST, IT MUST BE DISCLOSED TO THE CHIEF EXECUTIVE OFFICER. THE SECRETARY AND CHIEF EXECUTIVE OFFICER ARE RESPONSIBLE FOR REVIEWING THE ANNUAL CONFLICT OF INTEREST DISCLOSURES AND RESOLVING ANY POTENTIAL CONFLICT OF INTERESTS THAT MAY ARISE. THE COVERED PERSON IS REQUIRED TO REFRAIN FROM USING THEIR PERSONAL INFLUENCE TO ENCOURAGE THE ORGANIZATION TO ENTER INTO THE COVERED TRANSACTION. ADDITIONALLY, THEY MUST NOT PARTICIPATE IN ANY DISCUSSIONS REGARDING THE COVERED TRANSACTIONS WITH OFFICERS, DIRECTORS AND EMPLOYEES OF THE ORGANIZATION, EXCEPT TO RESPOND TO REQUESTS FOR INFORMATION. IF THE TRANSACTION IS DEEMED TO BE REASONABLE BY THE DISINTERESTED DIRECTORS (IN THE CASE OF A CONFLICT INVOLVING A DIRECTOR OR THE CHIEF EXECUTIVE OFFICER) OR CHIEF EXECUTIVE OFFICER (IN THE CASE OF A CONFLICT INVOLVING ANOTHER OFFICER OR KEY EMPLOYEE), THE ORGANIZATION MAY ENTER INTO THE TRANSACTION, AS LONG AS IT IS FAIR AND REASONABLE TO THE ORGANIZATION. SIMILAR TO THE COVERED PERSONS, ALL EMPLOYEES ARE REQUIRED TO COMPLETE A CONFLICT OF INTEREST CERTIFICATION UPON COMMENCING EMPLOYMENT AND TO UPDATE THE CERTIFICATION ANNUALLY, AND AT ANY TIME THERE IS A CHANGE THAT REQUIRES DISCLOSURE. THE HEAD OF COMPLIANCE & RISK MANAGEMENT IS RESPONSIBLE FOR REVIEWING THE CERTIFICATIONS AND ADMINISTERING AND MAINTAINING THE POLICY. THE POLICY RETAINS THAT IF AN OFFICER, DIRECTOR, OR MEMBER OF SENIOR LEADERSHIP BECOMES AWARE OF A TRANSACTION THAT COULD CAUSE A CONFLICT OF INTEREST, THEY ARE TO IMMEDIATELY DISCLOSE SUCH TO THE SECRETARY OF THE ORGANIZATION. PROCEDURES FOR RESOLVING A COVERED TRANSACTION AFTER DISCLOSURE TO THE SECRETARY REMAIN IN PLACE AS OUTLINED ABOVE. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF THE BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE USES AN INDEPENDENT REVIEW, COMPARABILITY DATA AND CONTEMPORANEOUS SUBSTANTIATION TO ESTABLISH TOTAL REMUNERATION PACKAGES FOR THE CEO, OFFICERS, AND CERTAIN KEY EMPLOYEES. THE BOARD IS PRESENTED WITH STUDY DATA, REVIEWS IT TO DETERMINE REASONABLENESS, AND THEN APPROVES TOTAL REMUNERATION ACCORDINGLY. ALL SUCH OFFICER AND CERTAIN KEY EMPLOYEE TOTAL REMUNERATION PACKAGES ARE REVIEWED AND APPROVED BY THE BOARD ANNUALLY. THE MOST RECENT COMPENSATION STUDY FOR PURPOSES OF THIS COMPENSATION PERIOD WAS CONDUCTED BY AN INDEPENDENT CONSULTANT IN 2022. COMPARABILITY DATA IS ALSO USED TO ESTABLISH COMPENSATION PACKAGES FOR OTHER EMPLOYEES. COMPENSATION PACKAGES FOR OTHER EMPLOYEES ARE APPROVED BY THE CEO ANNUALLY, BASED ON A COMPENSATION PHILOSOPHY ORIGINALLY APPROVED BY THE BOARD. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE'S FINANCIAL STATEMENTS ARE CONSOLIDATED WITH BILL & MELINDA GATES FOUNDATION, AND THE CONSOLIDATED FINANCIAL STATEMENTS ARE AVAILABLE AT WWW.GATESFOUNDATION.ORG. FORM 990, PART VI, SECTION A, LINE 9 ANY OFFICER, DIRECTOR, TRUSTEE, OR KEY EMPLOYEE THAT IS OR WAS AN EMPLOYEE OF THE BILL & FOUNDATION CAN BE REACHED AT THE FOLLOWING ADDRESS. FOR 2022, THIS INCLUDES SUSAN DESMOND-HELLMANN, CAROLYN AINSILE, TREVOR MUNDEL, HELENE MADONICK, AND TONI HOOVER: P.O. BOX 23350 SEATTLE, WA 98102 FORM 990, PART IX, LINE 11G OTHER FEES FOR SERVICES: PROGRAM SERVICE EXPENSES 17,708,332. MANAGEMENT AND GENERAL EXPENSES 910,710. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 18,619,042. SCIENTIFIC CONSULTING AND TECHNICAL ASSISTANCE: PROGRAM SERVICE EXPENSES 53,243,592. MANAGEMENT AND GENERAL EXPENSES 67,601. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 53,311,193. OPERATIONAL ASSISTANCE: PROGRAM SERVICE EXPENSES 35,000. MANAGEMENT AND GENERAL EXPENSES 2,982,382. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 3,017,382. FORM 990, PART XI, LINE 9: CONTRIBUTION ADJUSTMENT -15,000. BILL & MELINDA GATES FOUNDATION (BMGF) PO BOX 23350 SEATTLE WA 98102 562618866 GRANTMAKING FOUNDATION WA 501(C)(3) PF N/A 0 GATES PHILANTHROPY PARTNERS PO BOX 23350 SEATTLE WA 98102 473290897 GRANTMAKING PUBLIC CHARITY WA 501(C)(3) 7 BILL & MELINDA GATES FOUNDATION 1 BILL & MELINDA GATES FOUNDATION TRUST (BMGFT) PO BOX 23350 SEATTLE WA 98102 911663695 GRANTMAKING FOUNDATION WA 501(C)(3) PF N/A 0 ACCELERATOR GPS SIDE CAR FUND LP PO BOX 13329 RESEARCH TRIANGLE PARK NC 27709 814667411 PROGRAM RELATED INVESTMENT OF BMGF DE N/A 0 0 GREENBRIAR AS HOLDINGS LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 981208908 INVESTMENT OF BMGFT CJ N/A 0 0 GREENBRIAR EQUITY FUND III AIV NV LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 981208417 INVESTMENT OF BMGFT CJ N/A 0 0 GREENBRIAR EQUITY FUND III-A AIV WFCI LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 981219020 INVESTMENT OF BMGFT CJ N/A 0 0 GREENBRIAR EQUITY FUND III-A LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 461543216 INVESTMENT OF BMGFT DE N/A 0 0 THE GLOBAL GOOD FUND I LLC 3150 139TH AVE SE BELLEVUE WA 98005 272796838 INVESTMENT OF BMGFT DE N/A 0 0 GREENBRIAR EQUITY FUND III AIV MM NV LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 811112433 INVESTMENT OF BMGFT DE N/A 0 0 AFRICAN AGRICULTURAL CAPITAL FUND LLC 6TH FLOOR TOWER A 1 CYBERCITY EBENE MP 981017696 PROGRAM RELATED INVESTMENT OF BMGF MP N/A C 1 GREENBRIAR AS LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 981208754 INVESTMENT OF BMGFT CJ N/A C 0 CHROMIUM FUND LP 712 FIFTH AVE SUITE 17F NEW YORK NY 10019 871458828 INVESTMENT OF BMGFT CJ N/A C 0 DERBY FUND 3 712 FIFTH AVE SUITE 17F NEW YORK NY 10019 981693314 INVESTMENT OF BMGFT CJ N/A C 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0